Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Acneiform dermatitis

MedGen UID:: 68607
•Concept ID:: C0234894
•: Disease or Syndrome

Synonyms:	Acneiform Dermatitis; acneiform dermatitis; Rash acneiform

Monarch Initiative:	MONDO:0006521

Definition

Cutaneous eruptions resembling acne, characterized by the presence of papulonodules, pustules, comedones, or cysts in the face, trunk, and extremities. Causes include infections and the use of certain medications (e.g., antibiotics and steroids). [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVAcneiform dermatitis

Pathological Conditions, Signs and Symptoms
- Pathological process
  - Disease
    - Disorder by Site
      - Skin disorder
        Dermatitis
        Acneiform dermatitis
        Epidermal Growth Factor Receptor Inhibitor-Induced Acneiform Lesion

Professional guidelines

PubMed

The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.

Trullas A, Delgado J, Koenig J, Fuerstenau U, Dedorath J, Hausmann S, Stock T, Enzmann H, Pignatti F
ESMO Open 2021 Feb;6(1):100031. Epub 2021 Jan 8 doi: 10.1016/j.esmoop.2020.100031. PMID: 33422765 Free PMC Article

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data.

Abdel-Rahman O, ElHalawani H, Ahmed H
Clin Transl Oncol 2016 Aug;18(8):848-58. Epub 2015 Oct 30 doi: 10.1007/s12094-015-1438-0. PMID: 26519363

Differential diagnosis of facial acne on black skin.

Poli F
Int J Dermatol 2012 Nov;51 Suppl 1:24-6, 27-9. doi: 10.1111/j.1365-4632.2012.05559.x. PMID: 23210948

See all (3)

Recent clinical studies

Etiology

Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.

Brueckl WM, Reck M, Schäfer H, Neben K, Griesinger F, Rawluk J, Krüger S, Kokowski K, Ficker JH, Möller M, Schueler A, Laack E
J Geriatr Oncol 2023 Jan;14(1):101394. Epub 2022 Oct 30 doi: 10.1016/j.jgo.2022.10.009. PMID: 36323612

Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).

Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y
Support Care Cancer 2021 May;29(5):2327-2334. Epub 2020 Sep 11 doi: 10.1007/s00520-020-05765-7. PMID: 32918131 Free PMC Article

Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.

Abdel-Rahman O, ElHalawani H, Ahmed H
Future Oncol 2015;11(24):3307-19. Epub 2015 Nov 12 doi: 10.2217/fon.15.265. PMID: 26561878

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R
Lancet Oncol 2013 Mar;14(3):249-56. Epub 2013 Feb 13 doi: 10.1016/S1470-2045(13)70024-X. PMID: 23414587

Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.

Doi T, Ohtsu A, Tahara M, Tamura T, Shirao K, Yamada Y, Otani S, Yang BB, Ohkura M, Ohtsu T
Int J Clin Oncol 2009 Aug;14(4):307-14. Epub 2009 Aug 25 doi: 10.1007/s10147-008-0855-2. PMID: 19705240

See all (16)

Diagnosis

Facial dermatitis in a healthy 9-year-old boy.

Hiep A, Gross E
JAAPA 2022 Sep 1;35(9):37-40. doi: 10.1097/01.JAA.0000854540.40254.d0. PMID: 36007117

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.

Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE
Clin Cancer Res 2019 Oct 1;25(19):5752-5758. Epub 2019 Jul 15 doi: 10.1158/1078-0432.CCR-18-3453. PMID: 31308059 Free PMC Article

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.

Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, Cristofanilli M
Breast Cancer Res Treat 2016 Nov;160(1):91-99. Epub 2016 Sep 21 doi: 10.1007/s10549-016-3979-5. PMID: 27654971

Differential diagnosis of facial acne on black skin.

Poli F
Int J Dermatol 2012 Nov;51 Suppl 1:24-6, 27-9. doi: 10.1111/j.1365-4632.2012.05559.x. PMID: 23210948

Chronic granulomatous disease: two members of a single family with different dermatologic manifestations.

Luis-Montoya P, Sáez-de Ocariz Mdel M, Vega-Memije ME
Skinmed 2005 Sep-Oct;4(5):320-2. doi: 10.1111/j.1540-9740.2005.03927.x. PMID: 16282759

See all (8)

Therapy

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Stathis A, Tolcher AW, Wang JS, Renouf DJ, Chen LC, Suttner LH, Freshwater T, Webber AL, Nayak T, Siu LL
Invest New Drugs 2023 Jun;41(3):380-390. Epub 2023 Apr 11 doi: 10.1007/s10637-022-01326-3. PMID: 37040046 Free PMC Article

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.

Wang X, Luo Z, Chen J, Chen Y, Ji D, Fan L, Chen L, Zhao Q, Hu P, Sun P, Jia Z, Guo J, Si L
BMC Med 2023 Jan 4;21(1):2. doi: 10.1186/s12916-022-02669-7. PMID: 36600247 Free PMC Article

Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.

Abdel-Rahman O, ElHalawani H, Ahmed H
Future Oncol 2015;11(24):3307-19. Epub 2015 Nov 12 doi: 10.2217/fon.15.265. PMID: 26561878

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Dehydroepiandrosterone in systemic lupus erythematosus.

van Vollenhoven RF
Rheum Dis Clin North Am 2000 May;26(2):349-62. doi: 10.1016/s0889-857x(05)70142-3. PMID: 10768216

See all (39)

Prognosis

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.

Yang L, Zhang W, Fan N, Cao P, Cheng Y, Zhu L, Luo S, Zong H, Bai Y, Zhou J, Deng Y, Ba Y, Liu T, Aili M, Yin X, Gu K, Dai G, Ying J, Shi J, Gao Y, Li W, Yu G, Xie L, Gai W, Wang Y, Meng P, Shi Y
EBioMedicine 2024 Feb;100:104966. Epub 2024 Jan 13 doi: 10.1016/j.ebiom.2024.104966. PMID: 38217945 Free PMC Article

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E
Eur J Cancer 2018 Nov;104:1-8. Epub 2018 Oct 1 doi: 10.1016/j.ejca.2018.07.011. PMID: 30278378

Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.

Abdel-Rahman O, ElHalawani H, Ahmed H
Future Oncol 2015;11(24):3307-19. Epub 2015 Nov 12 doi: 10.2217/fon.15.265. PMID: 26561878

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC
Clin Cancer Res 2014 Aug 15;20(16):4251-61. Epub 2014 Jun 19 doi: 10.1158/1078-0432.CCR-14-0341. PMID: 24947927

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.

Sonis S, Treister N, Chawla S, Demetri G, Haluska F
Cancer 2010 Jan 1;116(1):210-5. doi: 10.1002/cncr.24696. PMID: 19862817

See all (10)

Clinical prediction guides

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Target Oncol 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. PMID: 33170484

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Differential diagnosis of facial acne on black skin.

Poli F
Int J Dermatol 2012 Nov;51 Suppl 1:24-6, 27-9. doi: 10.1111/j.1365-4632.2012.05559.x. PMID: 23210948

See all (21)